18,779 AgelessRx members have reported their NAD+ results. Among NAD+ members who answered the 60-day check-in, the outcome most often rated Good or better was overall health: 85% of 2,183 answers. The least often was fatigue at 61% of 3,421 answers. 0.6% rated overall health Poor or Very Poor.
Updated 11/3/2026
Share of treated orders that answered a check-in, by days since approval
Rated Good or better, by check-in
Level: share of check-in answers rating the outcome Good, Very Good or Excellent
Among NAD+ members who answered the 60-day check-in, the outcome most often rated Good or better was overall health: 85% of 2,183 answers. The least often was fatigue at 61% of 3,421 answers. 0.6% rated overall health Poor or Very Poor.
| Outcome | Goal | 30 days 12,900 answered | 60 days 8,817 answered | 90 days 3,060 answered |
|---|---|---|---|---|
| Sleep quality | Sleep | 58% | 63% | 66% |
| Fatigue | Energy & Focus | 56% | 61% | 63% |
| Recovery from physical activity | Longevity | 70% | 74% | 76% |
| Memory, concentration and cognition | Energy & Focus | 68% | 73% | 75% |
| Overall health | Overall | 83% | 85% | 87% |
| Energy | Energy & Focus | 64% | 70% | 73% |
How this was measured: Current check-ins. Members rate the outcome at a baseline check-in around day 3 and again at each later check-in, so the figure is a change against that member's own starting point.
Reported an improvement, by check-in
Level: share of check-in answers reporting a mild, moderate or significant improvement since starting
Among NAD+ members who answered the 60-day check-in, the outcome most often reported as improved was energy: 78% of 5,177 answers. The least often was appetite regulation at 20% of 2,397 answers. 0.6% said energy had gotten worse.
| Outcome | Goal | 30 days 12,900 answered | 60 days 8,817 answered | 90 days 3,060 answered |
|---|---|---|---|---|
| Cognitive function | Energy & Focus | 52% | 60% | 49% |
| Energy | Energy & Focus | 73% | 78% | 78% |
| Mood | Mood & Mental Health | 62% | 69% | 70% |
| Recovery time | Longevity | 58% | 66% | 66% |
| Physical endurance | Energy & Focus | 62% | 71% | 72% |
| Weight | Weight Management | 31% | 43% | 46% |
| Cravings | Weight Management | 23% | 23% | 21% |
| Appetite regulation | Weight Management | 20% | 20% | 19% |
| Mental clarity | Energy & Focus | 62% | 68% | 73% |
| Fertility | Sexual Health | 16% | 24% | 24% |
How this was measured: Legacy check-ins. These check-ins began at day 30 and asked whether the member had seen an improvement since starting, so the figure is what members reported rather than a measured change from a baseline.
Reported losing weight, by check-in
Level: share of check-in answers reporting any weight lost since starting
Among NAD+ members who answered the 60-day check-in, 25% of 2,118 answers reported losing weight. 7.9% reported gaining weight.
| Outcome | Goal | 30 days 12,900 answered | 60 days 8,817 answered | 90 days 3,060 answered |
|---|---|---|---|---|
| Weight | Weight Management | 24% | 25% | 27% |
How this was measured: Current check-ins. Members rate the outcome at a baseline check-in around day 3 and again at each later check-in, so the figure is a change against that member's own starting point.
No or mild symptoms, by check-in
Level: share of check-in answers rating the symptom none, very mild or mild
Among NAD+ members who answered the 30-day check-in, the outcome most often rated none or mild was poor memory: 81% of 551 answers. The least often was poor concentration at 78% of 569 answers. 5.3% rated poor memory severe or very severe.
| Outcome | Goal | 30 days 12,900 answered |
|---|---|---|
| Poor concentration | Energy & Focus | 78% |
| Poor memory | Energy & Focus | 81% |
| Feeling cognitively sludgy | Energy & Focus | 80% |
How this was measured: Current check-ins. Members rate the outcome at a baseline check-in around day 3 and again at each later check-in, so the figure is a change against that member's own starting point.
Two or fewer symptom days a week, by check-in
Level: share of check-in answers with aches and pains on two or fewer of the past seven days
Among NAD+ members who answered the 60-day check-in, 92% of 3,395 answers reported aches and pains on two or fewer days a week. 6.8% reported aches and pains on five days a week or more.
| Outcome | Goal | 30 days 12,900 answered | 60 days 8,817 answered | 90 days 3,060 answered |
|---|---|---|---|---|
| Aches and pains | Longevity | 91% | 92% | 92% |
How this was measured: Current check-ins. Members rate the outcome at a baseline check-in around day 3 and again at each later check-in, so the figure is a change against that member's own starting point.
Improved vs own baseline, by check-in
Change: share of treated orders rating the outcome better than at their own first check-in; unchanged and worse stay in the denominator
Among NAD+ orders that answered the 60-day check-in, the outcome most often rated better than at the first check-in was fatigue: 47% of 1,821 treated orders. The least often was overall health at 34% of 1,044 treated orders. 11% rated fatigue worse than at their first check-in.
| Outcome | Goal | 30 days 12,900 answered | 60 days 8,817 answered | 90 days 3,060 answered |
|---|---|---|---|---|
| Fatigue | Energy & Focus | 43% | 47% | 46% |
| Recovery from physical activity | Longevity | 42% | 45% | 44% |
| Sleep quality | Sleep | 39% | 41% | 42% |
| Memory, concentration and cognition | Energy & Focus | 39% | 43% | 46% |
| Overall health | Overall | 32% | 34% | 40% |
| Energy | Energy & Focus | 47% | 47% | 47% |
How this was measured: Current check-ins. Members rate the outcome at a baseline check-in around day 3 and again at each later check-in, so the figure is a change against that member's own starting point.
Reported improvement, by check-in
Cumulative share of treated orders that had reported an improvement by each check-in
Share of NAD+ treated orders that had reported an improvement on any outcome: 65% by the 1st check-in (about 30 days), 81% by the 2nd (about 60 days), 86% by the 3rd (about 90 days). Cumulative, so each figure includes the ones before it.
| Outcome | Goal | 1st check-in (30 days) | 2nd (60 days) | 3rd (90 days) | 4th (120 days) | 5th (150 days) |
|---|---|---|---|---|---|---|
| Any outcome | — | 65% | 81% | 86% | 88% | 89% |
| Fatigue | Energy & Focus | 33% | 45% | 49% | 51% | 52% |
| Recovery from physical activity | Longevity | 32% | 43% | 47% | 49% | 50% |
| Sleep quality | Sleep | 30% | 41% | 45% | 47% | 48% |
| Memory, concentration and cognition | Energy & Focus | 29% | 41% | 45% | 47% | 48% |
| Overall health | Overall | 25% | 33% | 36% | 38% | 38% |
| Energy | Energy & Focus | 25% | 37% | 45% | 50% | 52% |
This curve is the one figure on the page that spans both sets of check-ins: it counts a first improvement on any outcome question the product has ever asked, so it is not comparable with the single-method figures above.
Side effects
Counted per member across every check-in for the product
| Side effect | Reported this side effect | Members |
|---|---|---|
| Burning During Injection | 8% | 14,796 |
| Soreness At Injection Site | 8% | 14,796 |
| Itching At Patch Site | 5% | 14,796 |
| Itching At Injection Site | 5% | 14,796 |
| Rash Following Use | 3% | 14,796 |
| Upset Stomach | 3% | 14,796 |
| Post-Nasal Drip To Throat | 2% | 14,796 |
| Rash At Injection Site | 2% | 14,796 |
| Diarrhea | 1% | 14,796 |
| Burning During Administration | 1% | 14,796 |
| Headache | 0% | 14,796 |
| Increased Anxiety/Jittery | 0% | 14,796 |
Worst severity reported, by side effect
| Side effect | Members rating | Very mild | Mild | Moderate | Severe |
|---|---|---|---|---|---|
| Burning During Injection | 597 | 54% | 36% | 8% | 2% |
| Soreness At Injection Site | 460 | 54% | 34% | 10% | 2% |
| Itching At Injection Site | 332 | 57% | 33% | 8% | 2% |
| Other | 288 | 23% | 40% | 25% | 13% |
| Upset Stomach | 174 | 22% | 48% | 22% | 9% |
| Itching At Patch Site | 157 | 17% | 49% | 17% | 17% |
| Rash Following Use | 141 | 15% | 48% | 18% | 18% |
| Diarrhea | 96 | 25% | 53% | 14% | 8% |
| Rash At Injection Site | 78 | 49% | 33% | 17% | 1% |
| Post-Nasal Drip To Throat | 44 | 45% | 43% | 9% | 2% |
Variants of this product
The figures above are for the whole family; each variant where it clears the floor
| Variant | Approved | Surveyed | Treated orders | Never reported a side effect |
|---|---|---|---|---|
| NAD Injection | 34,791 | 15,923 | 17,776 | 76% |
| NAD Nasal Spray | 6,771 | 1,580 | 1,630 | 70% |
| NAD Patch | 5,886 | 1,958 | 2,028 | 48% |
Who the members are
Surveyed members for this product
Frequently asked questions
How many members have reported outcomes for NAD+?
18,779 members have answered a check-in about NAD+, across 21,434 treated orders approved between 1/1/2023 and 11/3/2026.
How do people rate their results on NAD+?
Among NAD+ members who answered the 60-day check-in, the outcome most often rated Good or better was overall health: 85% of 2,183 answers. The least often was fatigue at 61% of 3,421 answers. 0.6% rated overall health Poor or Very Poor.
What improvements do people report on NAD+?
Among NAD+ members who answered the 60-day check-in, the outcome most often reported as improved was energy: 78% of 5,177 answers. The least often was appetite regulation at 20% of 2,397 answers. 0.6% said energy had gotten worse.
Do people lose weight on NAD+?
Among NAD+ members who answered the 60-day check-in, 25% of 2,118 answers reported losing weight. 7.9% reported gaining weight.
How do people on NAD+ rate their symptoms?
Among NAD+ members who answered the 30-day check-in, the outcome most often rated none or mild was poor memory: 81% of 551 answers. The least often was poor concentration at 78% of 569 answers. 5.3% rated poor memory severe or very severe.
How many symptom days a week do people on NAD+ report?
Among NAD+ members who answered the 60-day check-in, 92% of 3,395 answers reported aches and pains on two or fewer days a week. 6.8% reported aches and pains on five days a week or more.
How many people on NAD+ improve compared with when they started?
Among NAD+ orders that answered the 60-day check-in, the outcome most often rated better than at the first check-in was fatigue: 47% of 1,821 treated orders. The least often was overall health at 34% of 1,044 treated orders. 11% rated fatigue worse than at their first check-in.
How long does NAD+ take to work?
Share of NAD+ treated orders that had reported an improvement on any outcome: 65% by the 1st check-in (about 30 days), 81% by the 2nd (about 60 days), 86% by the 3rd (about 90 days). Cumulative, so each figure includes the ones before it.
What are the side effects of NAD+?
72% of the 14,796 NAD+ members asked never reported a side effect on the product's checklist at any check-in, and 28% reported at least one. The most often reported were Burning During Injection (8.5%), Soreness At Injection Site (8.0%), Itching At Patch Site (4.8%), each out of 14,796 members asked.
Where does this data come from?
Self-reported at routine check-ins. No placebo, no blinding, no control arm. Descriptive, not proof. Computed by the Applied Science team's clinical-outcomes notebooks; this page reads them, it does not recompute them. Regenerated from the medical record, each member counted once. An outcome percentage needs at least 100 answers; side-effect and population figures need 20 members.
Definitions and methodology
Every term on this page, how the check-ins are collected, and how to read the figures
Definitions
Improved vs own baseline. Share of treated orders whose rating of the outcome at that check-in was better than the same order's rating at its first check-in. Ratings that were already at the ceiling on day 0 cannot improve and are excluded. Orders rating the same or worse are in the denominator.
Reported improvement by. Cumulative share of treated orders that had reported an improvement on any outcome question by that check-in, adjusted for orders that were due a check-in and did not respond (the Applied Science team's normalized first-improvement curve). One positive answer on any question is enough and an order stays counted afterwards, so this is a cumulative, best-case estimate. No interval is published.
Reported a first improvement on this outcome by. The same normalized first-improvement estimate restricted to one outcome question.
Rated Good or better. Share of check-in answers in that 30-day bin that rated the outcome Good, Very Good or Excellent, out of answers that gave a rating from Very Poor to Excellent. Not applicable and not-tracking answers are excluded. This is a level, not a change, so it is what a product reports where its check-ins begin at 30 days and there is no day-0 rating to compare against.
Reported improvement on any measured outcome. Every answer to the have-you-seen-an-improvement check-in questions for the product in that 30-day bin, pooled across outcomes: the share that reported a mild, moderate or significant improvement. Not-tracking answers are excluded. Counts answers, so a member answering four questions contributes four times.
Answered positively on any measured outcome. For products whose check-ins rate outcomes or ask about satisfaction rather than asking about improvement: every answer to those questions in that 30-day bin, pooled across outcomes, and the share that was Good or better, satisfied or better, or none-to-mild. Counts answers, so a member answering several questions contributes several times.
Reported an improvement. Share of check-in answers in that 30-day bin reporting a mild, moderate or significant improvement in the outcome since starting, out of answers that gave a verdict (gotten worse, no noticeable improvement, or an improvement). Not-tracking answers are excluded. Asked on check-ins that do not rate the outcome on a Poor-to-Excellent scale; a level, not a change from a day-0 rating.
Reported losing weight. Share of check-in answers in that 30-day bin reporting any weight lost since starting, out of answers that gave a figure (gained, no change, or pounds lost). Not-tracking answers are excluded. A level, not a change from a day-0 rating.
Satisfied or very satisfied. Share of check-in answers in that 30-day bin answering satisfied, mostly satisfied, very satisfied or extremely satisfied, out of all satisfaction answers. Neutral and somewhat satisfied count against this figure.
No or mild symptoms. Share of check-in answers in that 30-day bin rating the symptom none, very mild or mild (or never, rarely, not at all, a little), out of all symptom answers. Moderate or worse counts against this figure.
Two or fewer symptom days a week. Share of check-in answers in that 30-day bin reporting aches and pains on two or fewer of the past seven days, out of all answers to that question.
Says it helps. Share of check-in answers in that 30-day bin saying the medication helps a lot or somewhat and continues to help, out of all answers to that question (including 'it was helpful but is no longer' and 'it never helped'). Trazodone asks this instead of rating the outcome.
Never reported a side effect. Share of members asked the side-effect checklist who did not select any side effect on any check-in for the product. Members who reported one at any check-in count against this figure even if a later check-in reported none. Not published where the checklist has no 'none' option or reached under half of surveyed members.
Reported any side effect. Share of surveyed members who selected at least one side effect on at least one check-in. The complement of never reported a side effect.
Reported this side effect. Share of surveyed members who selected the side effect on at least one check-in. Members can select several, so rates do not sum to the any-side-effect figure.
Worst severity reported. Among members who reported the side effect and rated its severity, the share whose worst rating across all their check-ins fell in each level.
How the figures are measured
How this was measured: Current check-ins. Members rate the outcome at a baseline check-in around day 3 and again at each later check-in, so the figure is a change against that member's own starting point.
How this was measured: Legacy check-ins. These check-ins began at day 30 and asked whether the member had seen an improvement since starting, so the figure is what members reported rather than a measured change from a baseline.
We have kept improving how these check-ins are collected, so an older product can be measured differently from a newer one, and a single product can use both where its goals were asked about at different times. Each table says which applies. Compare figures measured the same way: a gap between two different measures is a difference in the question, not in the result.
Where the data comes from. Follow-up check-ins in the medical record, processed by the Applied Science team's clinical-outcomes notebooks, one per product family. This page reads the frames those notebooks publish; nothing here is typed in or recomputed.
Side effects. Counted per member across every check-in for the product: a member who selected a side effect once is a reporter even if later check-ins selected none. Severity is the worst level a member ever rated.
Who is counted. Approvals from 1 January 2023. Surveyed members answered at least one check-in. Demographics show shares only under 100 surveyed members.
Every improvement figure has a worsened share beside it: the answers that were lower than the day-0 rating, or said gotten worse, gained weight, dissatisfied or severe. The rest were unchanged.
Check-in response falls with time. Each cell reports the share of all treated orders that answered a check-in in that 30-day bin; orders too recent to have reached the bin are in the denominator, so it understates the true response rate. Headline figures use the latest check-in up to 90 days that at least a quarter of orders answered, or a later one where it clears the same bar.
Intervals are 95% Wilson score intervals for a share. A triangle marks a figure whose interval is wider than 20 points; read it as a rough indication only. First-improvement curves are cumulative estimates and carry no interval.
An outcome percentage needs at least 100 answers. Where a check-in has fewer, no percentage is published for it and the cell shows a dash, because a share of a few dozen answers reads as far more certain than it is. Side-effect and population figures are published from 20 members or 20 treated orders. Demographic shares are shown without counts where a product has fewer than 100 surveyed members.
About this data. These figures are what AgelessRx members reported in check-in surveys after starting a product: 18,779 surveyed customers who checked in with their provider on their first and/or later check-ins between 1/1/2023 and 11/3/2026. All respondents are AgelessRx customers who were approved for a prescription after completing an assessment with a medical provider. The figures are not from a clinical trial, have no control group, and include only members who answered; fewer members answer at later check-ins, so they may overstate how many people improve. Actual results may vary. This data is not a guarantee of results or a substitute for advice from your provider.
Some products are compounded by a licensed pharmacy; compounded products are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness, or quality. Some products are FDA-approved medications used for purposes other than their approved indications. Supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Prescription products require an evaluation by a licensed provider. See each product’s page on agelessrx.com for Important Safety Information. This data is de-identified, and AgelessRx will not attempt to re-identify it.
